Autoantibodies could shape cancer risk, growth and response to immunotherapy

Scientists have long sought to understand why some people with no known risk factors develop cancer while others with significant risk never do. The answer may lie in immune proteins known as autoantibodies (auto-Abs), suggests a commentary published in Cell co-authored by a team that includes Jean-Laurent Casanova, M.D., Ph.D., a professor in the Center for the Genetics of Host Defense and Children's Medical Center Research Institute at UT Southwestern (CRI).

‘Pro version’ of cisplatin keeps its cancer-killing power while reducing side effects

Cisplatin is one of the most successful cancer medicines ever developed. Doctors use it to treat many cancers, including lung, ovarian, breast, testicular and head and neck cancers. However, cisplatin has a serious problem. It does not attack only cancer cells. It can also reach healthy organs and damage them. In particular, cisplatin can harm the kidneys and peripheral nerves. Patients receiving cisplatin often experience pain, tingling, numbness or weakness in their hands and feet. These side effects can become so severe that doctors must reduce the dose or stop treatment completely.